A3P Biomedical (A3P) is a company that specializes in advanced prostate cancer diagnostics. A3P’s main product, Stockholm3, is a clinically and commercially validated blood test for early detection and risk stratification of aggressive prostate cancer. A3P is headquartered in Stockholm, Sweden.

Stockholm3 is a blood-based prostate cancer test, that runs a combination of protein biomarkers, genetic biomarkers and clinical information through an algorithm to find the probability of clinically significant cancer at biopsy.

Stockholm3 has been evaluated in clinical studies including more than 90,000 men. It is extensively tested in large population-based screening trials, as well as in real world clinical utility studies in primary care, as a reflex test to PSA at values 1.5-20 ng/ml. Benefits include the ability to reduce unnecessary MRIs, benign and Grade Group 1 prostate biopsies for men with elevated PSA, while simultaneously improving detection of clinically significant cancers in men with low or normal PSA values. Using Stockholm3 leads to a more accurate risk assessment than the current PSA standard. Stockholm3 detects 41-89%% more men with aggressive prostate cancer and, at the same time, reduces over-detection by 37-52% compared to PSA.

Multiple Stockholm3 studies have been published in high-impact journals such as The Lancet Oncology, Journal of Clinical Oncology, and European Urology. The studies address both the specificity and sensitivity of Stockholm3 in multi-ethnic populations as well as health-economic benefits of implementing it in clinical care.

A3P Biomedical’s sustainability strategy is specifically tailored to our solutions, business, and corporate culture. The sustainability strategy is based on five of the UN Sustainable Development Goals and an integral part of our business model.

Sustainability

Our business contributes to the following sustainability goals

Good health and well-being
Gender equality
Decent work and economic growth
Sustainable consumption and production
Combating climate change

The Board

Martin Steinberg

Executive Chairman of the Board

Board member since 2020.

Martin Steinberg co-founded A3P Biomedical AB in 2020 and remains one of the company’s largest owners. In addition to leading the company, Martin focuses on business development. He has more than 20 years’ experience as an executive and entrepreneur from various industry sectors. His former positions include Investment Manager at the venture capital firm Litorina Kapital and Management Consultancy at Arthur D. Little. Martin holds an MBA from the Stockholm School of Economics.
Cecilia Edström

Board Member and acting Chief Financial Officer (CFO)

Board Member since 2021.

Cecilia Edström joined A3P as a Board member in 2021 and has been engaged as acting CFO since 2023. Cecilia has more than 20 years’ C-suite experience from several industries, including automotive, telecommunications and medtech. She previously served as CEO and Board member of Bactiguard AB, a Swedish company with global footprint focused on infection prevention. She is a Board member of BioArctic AB, Flerie AB and Neonode Inc, as well as an Advisory Board Member of the European Patient Safety Foundation (EUPSF). Cecilia holds a BSc in Economics and Finance from the Stockholm School of Economics.
Henrik Grönberg

Board Member

Board member since 2021.
Henrik has a M.D. and Ph.D. in Oncology at Umeå University. Henrik is a professor of cancer epidemiology at Karolinska Institutet, where he leads a research group with 35 researchers focused on prostate cancer. Henrik is a co-founder of A3P Biomedical, one of the company’s largest owners and a leading expert in prostate cancer.
Thomas von Koch

Board Member
Board member since 2023.
Thomas von Koch holds a master’s degree in Economics at the Stockholm School of Economics. He has 30 years of experience in entrepreneurship, finance and leadership. After a couple of years at Investor AB, he joined the global investment giant EQT in 1994 as one of the first team members. Thomas von Koch was CEO and Managing Partner of EQT from 2014 to 2019 and is today chairman of EQT Asia Pacific. He is since 2019 (also during the period 2005 to 2013) chairman of the board of the Swedish medical technology company Bactiguard AB, a company he co-founded and remains the main owner of.
Mark Quick

Board Member
Board member since 2022.
Mark Quick is a partner in Flerie which invests in venture and growth stage companies engaged in drug development and associated tools or applications tackling major medical challenges. He is also a board member of several portfolio companies including Empros, Microbiotica, Bohus Biotech and is also chairman of the board of Anacardio. Prior to Flerie, Mark Quick was responsible for Recipharm’s M&A operations and was part of the leadership committee. Before that he spent time at ICI, Medeva, Celltech and UCB in various business development and supply chain roles. He also has an MBA from The Open University.
Jeroen Tas

Board Member
Board member since 2023.
Jeroen Tas holds a master’s degree in Computer Science and Business Administration from the Vrije University, Amsterdam. He is an experienced innovation leader who, through his entrepreneurship and competence in large-scale digital transformation, information technology and digital health technology, develops companies. Jeroen Tas was Chief Innovation and Strategy Officer at Philips from 2017 to 2021. Prior to Philips, he was co-founder and President, COO and Vice Chairman of Mphasis, which was acquired by HP in 2006.

The Management

Martin Steinberg

Executive Chairman of the Board
Martin Steinberg co-founded A3P Biomedical AB in 2020 and remains one of the company’s largest owners. In addition to leading the company, Martin focuses on business development. He has more than 20 years’ experience as an executive and entrepreneur from various industry sectors. His former positions include Investment Manager at the venture capital firm Litorina Kapital and Management Consultancy at Arthur D. Little. Martin holds an MBA from the Stockholm School of Economics.
Ola Steinberg

Chief Executive Officer
Ola Steinberg co-founded A3P Biomedical AB in 2020 and remains one of the company’s largest owners. He was appointed CEO in 2024 in addition to his responsibility for Research and Development. Ola has more than 20 years’ experience of working in the interface between academia and industry, including being the project manager for Stockholm3 at Karolinska Institutet. He has expertise in IT and health logistics, and former positions include Management Consultancy at McKinsey & Co. Ola holds an MSc at the KTH Royal Institute of Technology, Stockholm.
Cecilia Edström

Board Member and acting Chief Financial Officer (CFO)
Cecilia Edström joined A3P as a Board member in 2021 and has been engaged as acting CFO since 2023. Cecilia has more than 20 years’ C-suite experience from several industries, including automotive, telecommunications and medtech. She previously served as CEO and Board member of Bactiguard AB, a Swedish company with global footprint focused on infection prevention. She is a Board member of BioArctic AB, Flerie AB and Neonode Inc, as well as an Advisory Board Member of the European Patient Safety Foundation (EUPSF). Cecilia holds a BSc in Economics and Finance from the Stockholm School of Economics.
Andreas Hoel

VP Marketing and Sales
Andreas Hoel joined A3P Biomedical in 2022 and has 25 years’ experience in life science, medical devices and diagnostics, including senior roles in sales and marketing at Agilent and Thermo Fisher Scientific. He has broad international experience from Europe, the USA and Asia-Pacific, and has been responsible for launching several new technology platforms. His work experience also includes start-ups at Personal Chemistry and Biotage. Andreas holds an MSc in Chemistry from Technical University of Denmark, and an MBA from Henley Management College.
Maria Jansson

VP Operations, Quality Assurance & Regulatory Affairs
Maria Jansson joined A3P Biomedical in 2021 and has 20 years’ experience in product development, manufacturing and regulatory work in the medtech industry. Prior to joining A3P she was VP Regulatory Affairs and Quality at the Handicare Group, and preious employers include AstraZeneca, Nobel Biocare and Implantica. Maria has an MSc in chemical engineering with specialization in pharmaceuticals from the University of Uppsala.
Hari Vigneswaran

Chief Medical Officer (CMO)

Hari Vigneswaran joined A3P as Director of Medical Affairs in 2022 and was promoted to CMO in 2024. He completed his general and urological surgical training at the University of Illinois in Chicago and is an active board-certified urologist. He has been a researcher at the Karolinska Institute, with a focus on prostate cancer since 2018 and he has led and collaborated on several multi-national clinical trials. Hari holds a BSc in Materials Engineering from the University of Illinois Champaign-Urbana and a medical degree (M.D.) from the Warren Alpert Medical School of Brown University.